Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis

Area of Science:

• Oncology
• Immunology
• Skeletal Biology

Background:

• Melanoma frequently metastasizes to bone, causing significant morbidity and mortality.
• The tumor microenvironment (TME) is critical for melanoma progression, bone metastasis, and resistance to therapies.
• Immunosuppressive cells within the TME, including myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and cancer-associated fibroblasts (CAFs), promote immune evasion and bone destruction.

Purpose of the Study:

• To review the role of the TME in melanoma bone metastasis and immunotherapy resistance.
• To explore the mechanisms by which immunosuppressive cells drive osteolytic bone destruction.
• To discuss current and emerging immunotherapeutic strategies for melanoma.

Main Methods:

• Literature review synthesizing current knowledge on melanoma bone metastasis.
• Analysis of the interplay between the TME, immunosuppressive cells, and bone destruction.
• Evaluation of immune checkpoint inhibitors (ICIs) and novel combination therapies.

Main Results:

• The TME facilitates melanoma bone metastasis through both RANKL-dependent and -independent pathways.
• Immunosuppressive cells orchestrate immune evasion and osteolysis in the bone microenvironment.
• Resistance to current ICIs (anti-CTLA-4, anti-PD-1/PD-L1) is often linked to TME-mediated immunosuppression.

Conclusions:

• Targeting the TME is crucial for improving melanoma treatment outcomes.
• Combination therapies aimed at modulating the TME hold promise for overcoming immunotherapy resistance.
• Further research into TME dynamics is essential for developing more effective melanoma treatments.